Menarini and Radius have entered into a licensing agreement for the development and commercialization of the elacestrant.

Guide: Menarini acquires the global development and commercialization rights of elacestrant!----WALTHAM, Mass., July 27, 2020 /PRNewswire/ -- Menarini Group and RadiusHealth Inc(Nasdaq: RDUS) announced today that they have signed an exclusive global licensing agreement for the promotion of research and development and commercial applicationsResearchers are currently evaluating oral selective estrogen receptor degradation agent (SERD) as a hormone for the treatment of estrogen receptor-positive (ER-plus)/human epidermal growth factor receptor 2-negative (HER2-) postmenopausal breast cancer in postmenopausal women and menUnder the agreement, the Menarini Group will be responsible for the global commercialization of elacestrant applications upon successful completion of the REGISTRATION on the basis of positive results, according to the agreementElcin Barker Ergun, chief executive of Menarini Group, commented: "Following our recent acquisition of Stemline Therapeutics and its entry into the US biopharmaceutical market, elacestrant is a perfect complement to our global oncology portfolioOral selective estrogen receptor degradation agents are expected to produce new treatment models for breast cancer, and we look forward to advancing the development of elacestrant to provide patients with new treatment optionsKelly Martin, Radius's chief executive, commented: "The Menarini Group will be an excellent global partner for this projectGiven their recent investment and business expansion in the oncology sector, we are pleased to have this deal with themMartin added, "This deal is an important step for Radius and makes our development more flexible." "As part of the agreement, Radius will receive an advance of $30 million and a milestone of up to $320 million after successfully reaching the development and sales milestones in the future." The Menarini Group will pay A hierarchical royalty to Radius Health based on approximately 11-16% of global net salesRadius will continue and complete the EMERALD PHASE III study through the submission of a new drug application, and the associated costs will be reimbursed by the Menarini Group